Health Care · Medicinal Chemicals & Botanical Products · NYSE · CIK 896264 · FYE Jan 3 · Prices AT CLOSE 2026-07-30 (USD) — end-of-day, never a live or intraday quote
Last $22.17Day −2.21%Mkt cap $419MP/E (FY) 39.1×1Y −24.9%Off 52W high −31.4%Vol (1Y) 46.3%
Daily closing price, split-adjusted to the current basis; 3y shown of 5,294 bars on file. Sampled to 240 points — every point is a real close, none averaged. Price return, not total return (dividends excluded). Source marketstack.
| Short interest4.1% of sh out |
| Days to cover8.6d |
| 13F net flow (QoQ)−2.09% |
| Top-10 13F concentration64.9% |
| Next report (est.)2026-08-04 |
Short interest is FINRA semi-monthly, settlement 2026-07-15. 13F figures are quarterly filings, period 2026-Q1 — a lower bound on true ownership.
| P/E (FY)39.1× |
| Sales (TTM)$925.9M |
| Earnings (TTM)$8.9M |
| ROE2.0% |
| Net margin1.2% |
| ROIC2.9% |
| EPS growth 3Y−45.5% |
| Sales growth 3Y−2.5% |
Screener basis: ratios from the latest reported fiscal year; Sales/Earnings are trailing twelve months in the reporting currency (USD). The P/E is a trailing FULL-YEAR P/E, not TTM. Missing lines are absent from the filings, never imputed.
| YTD+12.9% |
| 1Y−24.9% |
| 3Y−65.8% |
| 5Y−76.7% |
| 10Y−67.7% |
| Since incept. (ann.)−0.1% |
Total return through 2026-07-30 · series begins 2005-07-11. Only the windows this history actually covers are shown.
| Ann. volatility (1Y)46.3% |
| Ann. volatility (3Y)41.4% |
| Sharpe (1Y)−0.44 |
| Sharpe (3Y)−0.66 |
| Max drawdown (1Y)−47.6% |
| Max drawdown (3Y)−74.6% |
| Beta (3Y vs SPY)1.19 |
Daily simple returns, annualized; drawdown is peak-to-trough within the window. Beta is the OLS slope of monthly returns on SPY's over three years. Each figure is labeled by the window it was measured over — they are not comparable across windows.
| Manager | Shares | Value | % sh out | QoQ |
|---|---|---|---|---|
| BlackRock, Inc. | 1.2M | $21M | 6.45% | +7.1% |
| PZENA INVESTMENT MANAGEMENT LLC | 1.1M | $19M | 6.01% | −2.2% |
| RENAISSANCE TECHNOLOGIES LLC | 1.0M | $18M | 5.51% | −11.3% |
| DIMENSIONAL FUND ADVISORS LP | 834,223 | $15M | 4.52% | −1.7% |
| Nantahala Capital Management, LLC | 810,074 | $14M | 4.39% | +38.5% |
| VANGUARD CAPITAL MANAGEMENT LLC | 479,043 | $8M | 2.60% | new |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 338,274 | $6M | 1.83% | new |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 333,112 | $6M | 1.80% | −5.9% |
Reported 13F long positions as filed for 2026-Q1 (change vs 2025-Q4). 13F covers US-listed long equity only — the sum is a LOWER BOUND on institutional ownership, never a total.
| Period end | Reported | EPS | EPS YoY | Revenue | Rev YoY |
|---|---|---|---|---|---|
| 2026-04-04 | 2026-05-05 | $0.41 | −16.3% | $250.2M | +0.3% |
| 2026-01-03 | 2026-02-18 | — | — | $226.2M | +5.9% |
| 2025-09-27 | 2025-10-22 | −$0.36 | −164.3% | $213.7M | +6.7% |
| 2025-06-28 | 2025-07-22 | $0.52 | −3.7% | $235.8M | +10.8% |
EPS and revenue as reported in this filer's own XBRL — our extraction of the filings, not a vendor consensus feed, and never a beat/miss claim (we carry no estimates). YoY compares the same fiscal quarter a year earlier. Next report 2026-08-04 is ESTIMATED from filing cadence (median gap 91d) — not company-confirmed.
Asia Pacific 28% · Greater China 19% · CN 17% · Americas And Europe 13% · US 10%
geographic · each slice's share of TAGGED segment revenue in the latest annual filing (XBRL, as filed). Untagged revenue is excluded from the denominator, so slices need not sum to consolidated sales.
